Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients.
D004999:Amifostine / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D011878:Radiotherapy / Q000009:adverse effects; D012463:Saliva / Q000378:metabolism; D016896:Treatment Outcome; D014987:Xerostomia / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism
D011837:Radiation-Protective Agents; D004999:Amifostine